Investigating the effect of magnesium supplement in patients with major depressive disorder under selective serotonin reuptake inhibitor treatment

• Published in: Journal of family medicine and primary care Vol. 11; no. 12; pp. 7800 - 7805
• Main Authors: Nazarinasab, Masoumeh, Behrouzian, Forouzan, Abdi, Leila, Sadegh Moghaddam, Amir Ali, Sadeghi, Susan
• Format: Journal Article
• Language: English
• Published: India Medknow Publications and Media Pvt. Ltd 01-12-2022; Wolters Kluwer - Medknow; Wolters Kluwer Medknow Publications
• Subjects: Antidepressants; Care and treatment; magnesium supplement; major depression disorder (mdd); Major depressive disorder; Mental illness; multifactorial disorder; Original; Phenols; multifactorial disorder; Magnesium supplement; major depression disorder (MDD)
• ISSN: 2249-4863; 2278-7135
• DOI: 10.4103/jfmpc.jfmpc_1164_22

Major depression disorder (MDD) is a mental disorder that affects millions of people worldwide. This disease has negative impacts on quality of life and psychological-related functions. This is a multifactorial disorder; both genetic background and environmental factors have their role. Antidepressants are prescribed as the first line of treatment for patients with depressive disorders. Selective serotonin reuptake inhibitor (SSRI) antidepressants are used to treat MDD and anxiety; however, some patients do not respond to them. Regarding that, magnesium plays a major role in mood regulation; therefore, this study aimed to investigate the role of magnesium supplement in patients with MDD and under an SSRI treatment regimen.
In this randomized, double-blind controlled trial, 60 patients with major depressive disorders based on the DSM-V diagnosis referred to Golestan Hospital in Ahvaz, Iran, were included. The eligible patients were categorized randomly into two thirty-people groups receiving magnesium (intervention) and placebo (control) along with SSRI for 6 weeks. To evaluate the depression status, the Beck II test was applied. Subjects were examined before and after the intervention.
There was no statistically significant difference between the two groups in terms of demographic characteristics (
> 0.05). The mean Beck scores at the beginning of the study and the second week after the intervention were not different between the two groups (
= 0.97,
= 0.56), whereas the mean Beck scores were lower in the intervention group than in the control group in the fourth and sixth weeks after the intervention (
= 0.02 and
= 0.001, respectively).
Administration of Mg supplement for at least 6 weeks might improve depression symptoms. It can also be considered as a potential adjunct treatment option for MDD patients who are under SSRI treatment.